145 citations
- Novartis (Switzerland)CH6 papers
- Roche (Switzerland)CH5 papers
- Merck & Co., Inc., Rahway, NJ, USA (United States)US3 papers
- Boehringer Ingelheim (Germany)DE2 papers
- Columbia UniversityUS2 papers
- GlaxoSmithKline (United States)US2 papers
- Janssen Research & Development (United States)US2 papers
- Nektar Therapeutics (United States)US2 papers
- Pomona CollegeUS2 papers
- University of California SystemUS2 papers
- University of MinnesotaUS2 papers
- AbbVie (Germany)DE1 paper
23 papers
Evaluating Bias Reduction Methods in Binary Emax Model for Reliable Dose-Response Estimation
Jiangshan Zhang, Vivek Pradhan, Yuxi Zhao
The Binary Emax model is widely employed in dose-response analysis during Phase II clinical studies to identify the optimal dose for subsequence confirmatory trials. The parameter…
Monitoring Adverse Events Through Bayesian Nonparametric Clustering Across Studies
Shijie Yuan, Kevin Roberts, Noirrit Kiran Chandra +2
We introduce a Bayesian nonparametric inference approach for aggregate adverse event (AE) monitoring across studies. The proposed model seamlessly integrates external data from his…
A robust score test in g-computation for covariate adjustment in randomized clinical trials leveraging different variance estimators via influence functions
Xin Zhang, Haitao Chu, Lin Liu +1
G-computation has become a widely used robust method for estimating unconditional (marginal) treatment effects with covariate adjustment in the analysis of randomized clinical tria…
Robust Emax Model Fitting: Addressing Nonignorable Missing Binary Outcome in Dose-Response Analysis
Jiangshan Zhang, Vivek Pradhan, Yuxi Zhao
The Binary Emax model is widely employed in dose-response analysis during drug development, where missing data often pose significant challenges. Addressing nonignorable missing bi…
Order-of-mutation effects on cancer progression: models for myeloproliferative neoplasm
Yue Wang, Blerta Shtylla, Tom Chou
We develop a modeling framework for cancer progression that distinguishes the order of two possible mutations. Recent observations and information on myeloproliferative neoplasms a…
Duration of and time to response in oncology clinical trials from the perspective of the estimand framework
Hans-Jochen Weber, Stephen Corson, Jiang Li +6
Duration of response (DOR) and time to response (TTR) are typically evaluated as secondary endpoints in early-stage clinical studies in oncology when efficacy is assessed by the be…